Danaher (NYSE:DHR) Stock Rating Lowered by Wall Street Zen

Danaher (NYSE:DHR) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Sunday, Wall Street Zen reports.

Other analysts also recently issued research reports about the stock. Wells Fargo & Company cut their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a report on Wednesday, July 22nd. Royal Bank Of Canada increased their price target on shares of Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a research report on Monday, October 5th. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. TD Cowen lifted their price objective on shares of Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Finally, Barclays boosted their price objective on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research report on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $235.41.

Danaher Trading Down 2.0%

DHR opened at $224.45 on Friday. Danaher has a twelve month low of $160.93 and a twelve month high of $242.80. The company has a 50-day simple moving average of $214.35 and a 200 day simple moving average of $196.30. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $157.78 billion, a price-to-earnings ratio of 28.21, a P/E/G ratio of 2.88 and a beta of 0.76.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion for the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the prior year, the company posted $0.77 earnings per share. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. Analysts predict that Danaher will post 8.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Gunderson Capital Management LLC bought a new stake in shares of Danaher during the third quarter worth about $765,000. EP Wealth Advisors LLC acquired a new stake in shares of Danaher in the 2nd quarter worth about $3,807,000. Frank Rimerman Advisors LLC lifted its position in Danaher by 181.9% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 40,855 shares of the conglomerate’s stock valued at $9,051,000 after acquiring an additional 26,363 shares in the last quarter. Birch Hill Investment Advisors LLC lifted its position in Danaher by 9.6% in the 3rd quarter. Birch Hill Investment Advisors LLC now owns 40,549 shares of the conglomerate’s stock valued at $8,984,000 after acquiring an additional 3,553 shares in the last quarter. Finally, Forbes J M & Co. LLP lifted its position in Danaher by 141.6% in the 3rd quarter. Forbes J M & Co. LLP now owns 4,276 shares of the conglomerate’s stock valued at $947,000 after acquiring an additional 2,506 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.